予後と毒性は,前線プログラム細胞死タンパク質1単独療法で治療された日本人の進行性メラノーマ患者の腫瘍負荷の変化により階層化されています
Ken Horisaki1,2, Shusuke Yoshikawa1, Wataru Omata1
1Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.
The Journal of dermatology
|September 6, 2025
まとめ
最良の腫瘍負荷変化 (BTBC) は,抗プログラム細胞死タンパク質-1 (PD-1) 療法で治療された進行性悪性黒色腫患者の予後と毒性を全体的な応答よりも良く予測します. 腫瘍の縮小は 毒性の増加と相関する
科学分野:
- 腫瘍学
- 免疫療法
- メラノマ 研究
背景:
- 免疫チェックポイント阻害剤 (ICI),特に抗プログラム細胞死タンパク質-1 (PD-1) 抗体は,進行性悪性黒色腫 (MM) の治療を進めている.
- しかし,患者の有意な割合はPD- 1単独治療に反応せず,反応率は患者の人口統計とメラノーマサブタイプによって異なります.
- 免疫関連の有害事象 (irAEs) は懸念事項であり,実際の結果の予測における最良の全体的な反応のような標準的な有効性測定の有用性は不明である.
研究 の 目的:
- 第4段階のMMの日本人の患者で,第一線PD-1単独治療を受けている患者で,最高の腫瘍負荷変化 (BTBC) と予後または毒性の関連性を評価する.
- BTBCの予測値と,長期的な結果と有害事象に対する最良の全体的な反応を比較する.
主な方法:
- 静岡がんセンター,日本のコホート研究.
- 第4段階のMM患者115人を対象に,第一線PD-1単独治療を行った.
- BTBC (標的病変のサイズの変化率) と全生存率,新しい病変の発生率,およびirAEsの相関の評価
主要な成果:
- 腫瘍負荷の減少に比例して予後が改善し,BTBC < 0%は長期的に好ましい予後を予測する有意な指標であった (p < 0. 001).
- 部分的応答と安定した疾患のグループでは,全生存期に有意な差は認められなかった (p = 0. 833).
- BTBC < 0% のグループでは,どのグレードのIrAEsの発生率も高かった (p < 0. 001),これは,腫瘍の縮小が増加した毒性に関連していることを示した.
結論:
- 最良の腫瘍負荷変化 (BTBC) は,PD- 1単独治療で治療された進行性MM患者の予後と毒性のより正確な予測因子である可能性があります.
- BTBC < 0%は好ましい予後を示し,BTBC ≥ 0%は新しい病変の発生に関係なく悪い予後を示します.
- 治療計画と毒性のモニタリングにBTBCを組み込むことは,第4段階のMMの管理戦略を強化し,将来的な検証を正当化することができます.
関連する概念動画
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


